Walleye Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,290
| Closed | -$132K | – | 4717 |
|
|
2026
Q1 | $132K | Sell |
3,290
-665
| -17% | -$14.3K | ﹤0.01% | 3548 |
|
|
2025
Q4 | $99.3K | Sell |
3,955
-138,203
| -97% | -$3.24M | ﹤0.01% | 3869 |
|
|
2025
Q3 | $3.22M | Buy |
142,158
+60,888
| +75% | +$1.42M | 0.01% | 1223 |
|
|
2025
Q2 | $1.41M | Sell |
81,270
-236,172
| -74% | -$4.37M | 0.01% | 1782 |
|
|
2025
Q1 | $6.94M | Sell |
317,442
-77,381
| -20% | -$2.14M | 0.03% | 610 |
|
|
2024
Q4 | $12.6M | Buy |
394,823
+292,743
| +287% | +$8.8M | 0.03% | 502 |
|
|
2024
Q3 | $2.94M | Buy |
102,080
+51,441
| +102% | +$1.91M | 0.01% | 1602 |
|
|
2024
Q2 | $1.94M | Sell |
50,639
-60,160
| -54% | -$2.72M | ﹤0.01% | 2138 |
|
|
2024
Q1 | $6.51M | Sell |
110,799
-36,875
| -25% | -$2.35M | 0.01% | 1110 |
|
|
2023
Q4 | $8.84M | Buy |
147,674
+13,691
| +10% | +$695K | 0.02% | 730 |
|
|
2023
Q3 | $5.1M | Buy |
133,983
+76,074
| +131% | +$3.34M | 0.01% | 1028 |
|
|
2023
Q2 | $5.28M | Sell |
57,909
-61,469
| -51% | -$5.3M | 0.02% | 700 |
|
|
2023
Q1 | $7.87M | Buy |
+119,378
| New | +$6.89M | 0.12% | 195 |
|
|
2022
Q2 | – | Sell |
-12,687
| Closed | -$645K | – | 2333 |
|
|
2022
Q1 | $645K | Sell |
12,687
-102,446
| -89% | -$4.52M | 0.02% | 871 |
|
|
2021
Q4 | $5.44M | Buy |
+115,133
| New | +$4.53M | 0.17% | 127 |
|
Other funds holding APLS
Walleye Capital's APLS Position: Q2 2026 in Review
Walleye Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,290 shares — an estimated $132K sold.
Walleye Capital first reported a position in APLS in Q4 2021 and held it in 15 quarters. The position peaked at $12.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Walleye Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Capital sold 3,290 Apellis Pharmaceuticals shares in Q2 2026, an estimated $132K.
- Walleye Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 15 quarters.
- Walleye Capital's Apellis Pharmaceuticals position peaked at $12.6M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.